Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (121-130 of 271) with videos related to

Pageof 28
Sort By:
Cancer|March 18, 2014
Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinomaSima Porten, Arlene O Siefker-Radtke, Lianchun Xiao, et al.
Cancer|October 10, 2006
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinomaNizar M Tannir, Lorenzo Cohen, Xuemei Wang, et al.
European Urology Oncology|November 1, 2025
Genotype-Phenotype Characterization of Lynch Syndrome-associated Upper Tract Urothelial CarcinomaCraig Labbate, Daniel A Igel, Donika Saporito, et al.
Cancer Research|November 26, 2014
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinomaMei Yee Koh, Vuvi Nguyen, Robert Lemos, et al.
Frontiers in Endocrinology|April 7, 2022
VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent ActionsCecilia Mathó, María Celia Fernández, Jenner Bonanata, et al.
The Oncologist|March 13, 2020
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-AnalysisJad Chahoud, Pavlos Msaouel, Matthew T Campbell, et al.
American Journal of Clinical Oncology|June 19, 2012
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinomaStephen L Richey, Pheroze Tamboli, Chaan S Ng, et al.
BJU International|November 18, 2015
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experienceMarc R Matrana, Tharakeswara Bathala, Matthew T Campbell, et al.
Oncotarget|May 29, 2018
Pilot study of dovitinib in patients with von Hippel-Lindau diseasePatrick Pilié, Elshad Hasanov, Surena F Matin, et al.
Oncotarget|December 25, 2015
Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survivalGuibin Xu, Yaodong Jiang, Yuansong Xiao, et al.
Pageof 28

Showing results (121-130 of 271) with videos related to

Sort By:
Pageof 28
Cancer|March 18, 2014
Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinomaSima Porten, Arlene O Siefker-Radtke, Lianchun Xiao, et al.
Cancer|October 10, 2006
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinomaNizar M Tannir, Lorenzo Cohen, Xuemei Wang, et al.
European Urology Oncology|November 1, 2025
Genotype-Phenotype Characterization of Lynch Syndrome-associated Upper Tract Urothelial CarcinomaCraig Labbate, Daniel A Igel, Donika Saporito, et al.
Cancer Research|November 26, 2014
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinomaMei Yee Koh, Vuvi Nguyen, Robert Lemos, et al.
Frontiers in Endocrinology|April 7, 2022
VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent ActionsCecilia Mathó, María Celia Fernández, Jenner Bonanata, et al.
The Oncologist|March 13, 2020
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-AnalysisJad Chahoud, Pavlos Msaouel, Matthew T Campbell, et al.
American Journal of Clinical Oncology|June 19, 2012
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinomaStephen L Richey, Pheroze Tamboli, Chaan S Ng, et al.
BJU International|November 18, 2015
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experienceMarc R Matrana, Tharakeswara Bathala, Matthew T Campbell, et al.
Oncotarget|May 29, 2018
Pilot study of dovitinib in patients with von Hippel-Lindau diseasePatrick Pilié, Elshad Hasanov, Surena F Matin, et al.
Oncotarget|December 25, 2015
Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survivalGuibin Xu, Yaodong Jiang, Yuansong Xiao, et al.
Pageof 28